Voyager Therapeutics, Inc. (VYGR)

8.36 +0.54 (+6.91%) At close: 04:00PM EDT

Voyager Therapeutics, Inc.

75 Hayden Avenue
Lexington, MA 02421
United States
857 259 5340
https://www.voyagertherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 162

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.	President, CEO & Director	1.01M	N/A	1958
Ms. Robin Swartz	COO, Principal Financial & Accounting Officer and Acting Chief Business Officer	661.98k	N/A	1971
Ms. Jacquelyn Fahey Sandell Esq., J.D.	Chief Legal Officer	538.16k	N/A	1971
Dr. Krystof Bankiewicz M.D., Ph.D.	Founder	N/A	N/A	N/A
Dr. Guangping Gao Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Mark A. Kay M.D., Ph.D.	Founder	N/A	N/A	1959
Dr. Phillip D. Zamore Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Todd Carter Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Ms. Michelle Quinn Smith	Chief Human Resources Officer	N/A	N/A	N/A
Dr. Maria Lopez-Bresnahan M.B.A., M.D.	Senior Vice President of Translational Medicine & Clinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Voyager Therapeutics, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.